Table 1.
Clinical characteristics of lung adenocarcinoma patients analyzed for EGFR and KRAS mutations
| Gender | Age (years) | Stage | Smoking history | Management | |
|---|---|---|---|---|---|
| 1 | M | 55 | IB | Yes | Chemo/Rad/Surgery/Erlotinib |
| 2 | M | 75 | IV | Yes | Chemo |
| 3 | M | 56 | IV | No | Surgery/Chemo/Erlotinib |
| 4 | F | 67 | IIIA | Yes | Surgery/Rad/Chemo/Erlotinib |
| 5 | F | 61 | IV | No | Erlotinib |
| 6 | F | 62 | IV | No | Chemo/Erlotinib |
| 7 | F | 68 | IV | Yes | Chemo |
| 8 | F | 51 | IIA | Yes | Chemo/Rad |
| 9 | M | 63 | IV | Yes | Chemo |
| 10 | F | 58 | IV | Yes | Chemo |
| 11 | M | 37 | I | Yes | NA |
| 12 | M | 76 | III | No | NA |
| 13 | M | 32 | IV | No | Chemo/Rad/Erlotinib |
| 14 | M | 62 | IV | Yes | Surgery/Chemo |
Abbreviations: M, male; F, female; Chemo, chemotherapy; Rad, radiation; NA, not available.